Perifosine enhances the sensitivity to oxaliplatin and 5-fluorourasil in PIK3CA-mutated colon cancer

被引：0
|
作者：
Takefuji, Honoka [1 ]
Tsubaki, Masanobu [1 ]
Takeda, Tomoya [1 ]
Matsuda, Takuya [1 ]
Kimura, Akihiro [1 ]
Nishida, Shozo [1 ]
机构：
[1] Kindai Univ, Dept Pharmacotherapy, Fac Pharm, Higashiosaka, Osaka, Japan
来源：
CANCER SCIENCE | 2023年 / 114卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-1343
引用
收藏
页码：680 / 680
页数：1
相关论文
共 50 条
  • [21] FDA Approves Inavolisib Combo for PIK3CA-Mutated, HR plus Breast Cancer
    Zhang, Jinwei
    CURRENT MEDICINAL CHEMISTRY, 2025,
  • [22] Outcome and mutational landscape of patients with PIK3CA-mutated metastatic breast cancer (mBC)
    Mosele, M. F.
    Lusque, A.
    Dien, A. Tran
    Droin, N.
    Le Tourneau, C.
    Lacroix, L.
    Bieche, I.
    Massard, C.
    Bertucci, F.
    Andre, F.
    ANNALS OF ONCOLOGY, 2019, 30
  • [23] Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer
    Andre, Fabrice
    Ciruelos, Eva
    Rubovszky, Gabor
    Campone, Mario
    Loibl, Sibylle
    Rugo, Hope S.
    Iwata, Hiroji
    Conte, Pierfranco
    Mayer, Ingrid A.
    Kaufman, Bella
    Yamashita, Toshinari
    Lu, Yen-Shen
    Inoue, Kenichi
    Takahashi, Masato
    Papai, Zsuzsanna
    Longin, Anne-Sophie
    Mills, David
    Wilke, Celine
    Hirawat, Samit
    Juric, Dejan
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (20): : 1929 - 1940
  • [24] Einsatz von Alpelisib beim fortgeschrittenen PIK3CA-mutierten MammakarzinomUse of alpelisib for PIK3CA-mutated advanced breast cancer
    Wolfram Malter
    Hakan Alakus
    Peter Mallmann
    Christiane Bruns
    Der Onkologe, 2019, 25 (8): : 724 - 725
  • [25] BYL719 (ALPELISIB) FOR THE TREATMENT OF PIK3CA-MUTATED, RECURRENT/ADVANCED CERVICAL CANCER
    Bogani, G.
    Bini, M.
    Ronzulli, D.
    Raspagliesi, F.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A12 - A12
  • [26] BYL719 (alpelisib) for the treatment of PIK3CA-mutated, recurrent/advanced cervical cancer
    Bogani, Giorgio
    Chiappa, Valentina
    Bini, Marta
    Ronzulli, Dominique
    Indini, Alice
    Conca, Elena
    Raspagliesi, Francesco
    TUMORI JOURNAL, 2023, 109 (02): : 244 - 248
  • [27] Role of Alpelisib in the Treatment of PIK3CA-Mutated Breast Cancer: Patient Selection and Clinical Perspectives
    Chang, Dwan-Ying
    Ma, Wei-Li
    Lu, Yen-Shen
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2021, 17 : 193 - 207
  • [28] BYL719 (alpelisib) for the treatment of PIK3CA-mutated, recurrent/advanced cervical cancer
    Bogani, G.
    Indini, A.
    Bini, M.
    Raspagliesi, F.
    ANNALS OF ONCOLOGY, 2021, 32 : S754 - S754
  • [29] Exceptional Response to Copanlisib in a Heavily Pretreated Patient With PIK3CA-Mutated Metastatic Breast Cancer
    Spathas, Nikolaos
    Economopoulou, Panagiota
    Kotsantis, Ioannis
    Oikonomopoulos, Nikolaos
    Psyrri, Amanda
    JCO PRECISION ONCOLOGY, 2020, 4 : 335 - 340
  • [30] Cell line models for drug discovery in PIK3CA-mutated colorectal cancers
    Voutsadakis, Ioannis A.
    MEDICAL ONCOLOGY, 2022, 39 (05)
12345